myelofibrosis

A pooled overall survival analysis of the ongoing Controlled Myelofibrosis Study with Oral JAK Inhibitor Therapy (COMFORT-I and -II) studies showed risk of death at three years was reduced by 35% in patients initially randomized to treatment with Jakavi(R) compared to those randomized to the placebo group.

Relative fluorescence intensity of myelofibrosis sections (primary myelofibrosis and acute monocytic leukemia with reticulin myelofibrosis) without 4',6-diamidino-2-phenylindole (DAPI) staining in 488-, 561-, and 633-nm channels, with that in 405-nm channel used as control.

Polycythemia Vera (PV) is a cancer originating from a disease-initiating stem cell in the bone marrow resulting in a chronic increase of red blood cells, white blood cells, and platelets, resulting in cardiovascular complications including thrombosis and embolism, as well as transformation to secondary myelofibrosis or leukemia.

Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) that can present as de novo (primary) MF (PMF) or as MF after transformation of polycythemia vera (PV) or essential thrombocythemia (ET).

Some of the common types of orphan blood disease, which lead to acquired orphan blood diseases, include Paroxysmal Nocturnal Hemoglobinuria (PNH), Idiopathic Thrombocytopenic Purpura (ITP), Myelodysplastic Syndrome (MDS), Myelofibrosis (MF), and Polycythemia Vera (PV).

Of the HHV-8 negative MCD (also named as idiopathic MCD [iMCD]), there is a peculiar subtype named TAFRO syndrome which constitutes a constellation of unique clinical manifestations (T: Thrombocytopenia, A: Anasarca, F: myelofibrosis, R: Renal dysfunction, and O: Organomegaly).

Impact is developing fedratinib for myelofibrosis and polycythemia vera.

Celgene has entered an agreement to acquire Impact Biomedicines for approximately $1.1 billion upfront and as much as $1.25 billion in payments based on regulatory milestones for myelofibrosis. Impact is developing fedratinib for myelofibrosis and polycythemia vera.

Primary myelofibrosis is classified in oncology under myoproliferative neoplasms.

Background and Objectives: The term myeloproliferative neoplasms (MPN) was first introduced by William Dameshek in 1951 to emphasize the clinicopathological similarities between chronic myeloid leukemia (CML), essential thrombocythemia (ET), polycythemia vera (PV), and with myeloid metaplasia (MMM) ( Also known as, chronic idiopathic myelofibrosis or primary myelofibrosis) Accordingly, these 4 disorders are currently referred to as "classic" MPN.

Idiopathic Myelofibrosis is a rare myeloproliferative disorder.

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by abnormal proliferation of megakaryocytes, bone marrow fibrosis, and extramedullary hematopoiesis.